Dr. CHAN Fuk Woo, Jasper

陳福和醫生

MBBS (HK), MD (HK), PDipID (HK), MRCP (UK), FRCP (Edin), FRCP (Glasg), FRCPath, FHKCPath, FHKAM (Pathology)

Deputy Chairperson & Clinical Associate Professor, Department of Microbiology, HKU

Deputy Chief-of-Service & Chief Physician, Department of Infectious Diseases and Microbiology, HKU-Shenzhen Hospital

Honorary Consultant, Department of Microbiology, Queen Mary Hospital

Email: jfwchan@hku.hk

HKU Scholars Hub: http://hub.hku.hk/cris/rp/rp01736

ORCID : https://orcid.org/0000-0001-6336-6657

Google Scholar: https://scholar.google.com/citations

Research Interests

Diagnosis, treatment, and control of emerging infectious diseases with pandemic potential and/or special relevance in Asia

biography

Dr. Jasper Fuk-Woo Chan is currently Assistant Dean (Global Engagement), Li Ka Shing Faculty of Medicine; HKU; Deputy Chairperson and tenured Clinical Associate Professor, Department of Microbiology, HKU; Deputy Chief-of-Service and Consultant, Department of Infectious Diseases and Microbiology, HKU-Shenzhen Hospital; and Honorary Consultant, Department of Microbiology, Queen Mary Hospital. He received his M.B.B.S. from HKU in 2005 and underwent postgraduate specialist training at the Department of Medicine and Department of Microbiology at Queen Mary Hospital from 2006-2012. He joined the Department of Microbiology at his alma mater as Clinical Assistant Professor in 2013. He was awarded the Sir Patrick Manson Gold Medal for the best M.D. thesis at HKU in 2017. He was elected as Fellow of the Infectious Diseases Society of America (FIDSA) in 2022 and as Member of the Hong Kong Young Academy of Sciences in 2024 (the first and only clinician-scientist).

As a clinical microbiologist actively managing patients with infectious diseases in Hong Kong and Shenzhen, Dr. Chan is particularly passionate about conducting research on the diagnosis, treatment and control of emerging infectious diseases with pandemic potential and/or special relevance to Asia. He has authored/co-authored more than 330 [over 120 (co-)first/corresponding] journal publications in these areas (Scopus: h-index 81, citations >39,400), including (co-)first/corresponding-author publications in The Lancet, Science, and Nature. Dr. Chan has been consistently ranked by Clarivate as one of the world’s top 1% scholars by citations since 2015 (http://hub.hku.hk/local/top1pc/top1pc.jsp) and as a “Highly Cited Researcher” (2 fields: “Microbiology” and “Immunology”) since 2021 (https://www.hku.hk/press/press-releases/detail/25372.html). He has served as expert member or ambassador of various international organizations, including as member of the WHO ad hoc Expert Group focused on COVID-19 disease modelling (WHOCOM) and Young Ambassador of Science of the American Society for Microbiology. He has been invited to chair sessions or speak at more than 70 international and regional conferences/symposia. He is a member of the Global Advisory Board of Clinical Microbiology Reviews, an Associate Editor/Editorial Board Member of Journal of Medical Virology, Open Forum Infectious Diseases, American Journal of Transplantation, Pathogens, BMC Microbiology, BMC Infectious Diseases, and Microbes & Immunity, and has been invited to review research papers for more than 50 journals (including The Lancet, NEJM, and Nature series) and grant applications for international/national funding agencies in USA and Europe [European Research Council (ERC), Switzerland (SNSF), France (ANR), the Netherlands (NWO), Austria (FWF), Poland (NCN), and Croatia (HRZZ)]. He has received external competitive research grants as Principal Coordinator/Investigator from the Ministry of Science and Technology (National Key R&D Programme of China) and National Natural Science Foundation of China (NSFC) (General Program) (mainland China), and Research Grants Council (RGC) [Collaborative Research Fund (CRF) and General Research Fund (GRF)] and Health and Medical Research Fund (HMRF) (Hong Kong), and own a number of patents on novel diagnostics and antivirals. He has mentored 38 Ph.D. and M.Phil. students at HKU. Dr. Chan’s team reported the world’s first familial cluster of COVID-19 that confirmed person-to-person transmission of SARS-CoV-2, which resulted in major control policy changes globally (Chan et al., Lancet 2020: 1 of 34 articles highlighted in the “200 years of The Lancet timeline”). His team also established the world’s first COVID-19 Syrian hamster model, which has become one of the most commonly used COVID-19 animal models worldwide.

Honours & Awards

External (International, National, and Regional):

2024: Elected Member of the Hong Kong Young Academy of Sciences

2023: First-author research article “Chan JF et al., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395:514-523” selected as one of the 34 landmark papers in the “200 Years of The Lancet” timeline (https://www.thelancet.com/lancet-200/timeline-infographic).

2023: Highly Cited Researcher 2023 (“Microbiology”) (Clarivate)

2023: Highly Cited Researcher 2023 (“Immunology”) (Clarivate)

2023 (since 2015): Top 1% scholar (Clarivate)

2023 (since 2019): Top 2% most-cited scientist (Stanford University)

2023: The 8th VCANBIO Award for Biosciences and Medicine (VABM) (Innovation Breakthrough Award) (The University of Chinese Academy of Sciences and VCANBIO Cell & Gene Engineering Corporation Limited)

2023: 2023 Dalton Horizon Prize (Bismuth cure for COVID-19) (Royal Society of Chemistry)

2023: Gold Medal (Bismuth-based Cocktail Therapy for Coronavirus) (The 48th Geneva International Exhibition of Inventions)

2023: The IDSA Leadership Institute: Community of Leaders (IDSA)

2022: Highly Cited Researcher 2022 (“Microbiology”) (Clarivate)

2022: Highly Cited Researcher 2022 (“Immunology”) (Clarivate)

2022: Fellow of the Infectious Diseases Society of America (FIDSA)

2022: Fellow of the Royal Society of Biology (FRSB)

2022: Fellow of the Institute of Biomedical Science (FIBMS)

2021: Highly Cited Researcher 2021 (“Microbiology”) (Clarivate)

2021: Highly Cited Researcher 2021 (“Immunology”) (Clarivate)

2021: Biomedicines 2021 Young Investigator Award (Biomedicines)

2021: Pathogens 2021 Young Investigator Award (Pathogens)

2021:   Emerging Microbes & Infections 2020 Best Paper Award (1st Place) (as first author) (Emerging Microbes & Infections)

2021: Prize for Best Original Research by Young Fellows (Gold Medal Winner) (Hong Kong Academy of Medicine)

2020: Lo Ying Shek Chi Wai Foundation Award for Young Investigator (Lo Ying Shek Chi Wai Foundation)

2020: Kylin Science and Technology Award Capital Excellent Science and Technology Innovation Award (Beijing Society of Science and Technology Professionals Capital, Beijing, People’s Republic of China)

2019 (since 2017): ASM Young Ambassador of Science to Hong Kong (American Society for Microbiology)

2019: State Scientific and Technological Progress Award (2nd Class Award) (the National Government of the People’s Republic of China)

2019: The Most Promising Young Researcher Award (Food and Health Bureau of the HKSAR Government)

2019: The Best Poster Award (Young Investigator Category at the 32nd International Conference on Antiviral Research by International Society for Antiviral Research)

2018: The Chinese Medical Science and Technology Award (2nd Class Award) (Chinese Medical Association)

2015: ASV Medical Virology Club Travel Award (American Society for Virology)

2011: Best Presentation Prize at the 7th Trainee Presentation Session (The Hong Kong College of Pathologists)

2010: Outstanding Team Award (Hospital Authority of Hong Kong)

 

Internal (The University of Hong Kong & HKUMed):

2022:   HKU Research Output Prize (2021-2022) (as co-first author for the best research output in HKU LKS Faculty of Medicine in 2021)

2022: Faculty Outstanding Research Output Awards (2021-2022) (x3 as co-first author & co-author)

2022: Gold-Class 10-Year Anniversary Excellent Team Award (as Deputy Chief-of-Service) (HKU-Shenzhen Hospital)

2021: HKU Outstanding Young Researcher Award (The University of Hong Kong)

2021:   HKU Research Output Prize (2020-2021) (as first author for the best research output in HKU LKS Faculty of Medicine in 2020)

2021: Faculty Outstanding Research Output Awards (2020-2021) (x2 as co-author)

2018: Sir Patrick Manson Gold Medal (LKS Faculty of Medicine, HKU)

2016: HKU Research Output Prize (as co-author for the best research output in HKU LKS Faculty of Medicine in 2015)

Selected Publications (2-year impact factor & Scopus citations)

Research Articles:

 

  1. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. Epub 2020 Jan 24. (IF: 168.9, citations: 6,158)

      – This article reported the world’s first evidence of person-to-person transmission of SARS-CoV-2 and was selected by The Lancet as one of the 34 papers in the ”200 Years of The Lancet” timeline (https://www.thelancet.com/lancet-200/timeline-infographic).

  1. Yuan S, Ye ZW, Liang R, Tang K, Zhang AJ, Lu G, Ong CP, Man Poon VK, Chan CC, Mok BW, Qin Z, Xie Y, Chu AW, Chan WM, Ip JD, Sun H, Tsang JO, Yuen TT, Chik KK, Chan CC, Cai JP, Luo C, Lu L, Yip CC, Chu H, To KK, Chen H, Jin DY, Yuen KY, Chan JF (corresponding). Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters.  Science. 2022 Jul 22;377(6604):428-433. Epub 2022 Jun 23. (IF: 56.9, citations: 78)
  2. Shuai H, Chan JF (co-first), Hu B, Chai Y, Yuen TT, Yin F, Huang X, Yoon C, Hu JC, Liu H, Shi J, Liu Y, Zhu T, Zhang J, Hou Y, Wang Y, Lu L, Cai JP, Zhang AJ, Zhou J, Yuan S, Brindley MA, Zhang BZ, Huang JD, To KK, Yuen KY, Chu H. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022 Mar;603(7902):693-699. Epub 2022 Jan 21. (IF: 64.8, citations: 357)
  3. Chu H, Hou Y, Yang D, Shuai H, Yoon C, Shi J, Chai Y, Yuen TT, Hu B, Li C, Zhao X, Wang Y, Huang X, Lee KS, Luo C, Cai JP, Poon VK, Chan CC, Zhang AJ, Yuan S, Sit KY, Foo DC, Au WK, Wong KK, Zhou J, Kok KH, Jin DY, Chan JF (co-corresponding), Yuen KY. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature. Sep;609(7928):785-792. Epub 2022 Aug 3. (IF: 64.8, citations: 29)
  4. Yuan S, Yin X, Meng X, Chan JF (co-first), Ye ZW, Riva L, Pache L, Chan CC, Lai PM, Chan CC, Poon VK, Lee AC, Matsunaga N, Pu Y, Yuen CK, Cao J, Liang R, Tang K, Sheng L, Du Y, Xu W, Lau CY, Sit KY, Au WK, Wang R, Zhang YY, Tang YD, Clausen TM, Pihl J, Oh J, Sze KH, Zhang AJ, Chu H, Kok KH, Wang D, Cai XH, Esko JD, Hung IF, Li RA, Chen H, Sun H, Jin DY, Sun R, Chanda SK, Yuen KY. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature. 2021 May;593(7859):418-423. Epub 2021 Mar 16. (IF: 64.8, citations: 134)
  5. Liu L, Iketani S, Guo Y, Chan JF (co-first), Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY, Ho DD. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. Nature. 2022 Feb;602(7898):676-681. Epub 2021 Dec 23. (IF: 64.8, citations: 769)
  6. Iketani S, Liu L, Guo Y, Liu L, Chan JF (co-first), Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z, Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022 Apr;604(7906):553-556. Epub 2022 Mar 3. (IF: 64.8, citations: 487)
  7. Xia S, Chan JF (co-first), Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 2022 Apr;32(4):404-406. Epub 2022 Jan 27. (IF: 44.1, citations: 27)
  8. Yuan S, Yan B, Cao J, Ye ZW, Liang R, Tang K, Luo C, Cai J, Chu H, Chung TW, To KK, Hung IF, Jin DY, Chan JF (co-corresponding), Yuen KY. SARS-CoV-2 exploits host DGAT and ADRP for efficient replication. Cell Discov. 2021 Oct 26;7(1):100. (IF: 33.5, citations: 28)
  9. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013 Dec;67(6):606-16. Epub 2013 Oct 3. (IF: 28.2, citations: 303)
  10. Chu H, Hu B, Huang X, Chai Y, Zhou D, Wang Y, Shuai H, Yang D, Hou Y, Zhang X, Yuen TT, Cai JP, Zhang AJ, Zhou J, Yuan S, To KK, Chan IH, Sit KY, Foo DC, Wong IY, Ng AT, Cheung TT, Law SY, Au WK, Brindley MA, Chen Z, Kok KH, Chan JF (co-corresponding), Yuen KY. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. Nat Commun. 2021 Jan 8;12(1):134. (IF: 16.6, citations: 100)
  11. Qiao W, Lau HE, Xie H, Poon VK, Chan CC, Chu H, Yuan S, Yuen TT, Chik KK, Tsang JO, Chan CC, Cai JP, Luo C, Yuen KY, Cheung KM, Chan JF (co-corresponding), Yeung KW. SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters. Nat Commun. 2022 May 9;13(1):2539. (IF: 16.6, citations: 23)
  12. Chan JF, Oh YJ, Yuan S, Chu H, Yeung ML, Canena D, Chan CC, Poon VK, Chan CC, Zhang AJ, Cai JP, Ye ZW, Wen L, Yuen TT, Chik KK, Shuai H, Wang Y, Hou Y, Luo C, Chan WM, Qin Z, Sit KY, Au WK, Legendre M, Zhu R, Hain L, Seferovic H, Tampé R, To KK, Chan KH, Thomas DG, Klausberger M, Xu C, Moon JJ, Stadlmann J, Penninger JM, Oostenbrink C, Hinterdorfer P, Yuen KY, Markovitz DM. A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. Cell Rep Med. 2022 Oct 18;3(10):100774. Epub 2022 Sep 29. (IF: 14.3, citations: 12)
  13. Chan JF, Hu B, Chai Y, Shuai H, Liu H, Shi J, Liu Y, Yoon C, Zhang J, Hu JC, Hou Y, Huang X, Yuen TT, Zhu T, Li W, Cai JP, Luo C, Yip CC, Zhang AJ, Zhou J, Yuan S, Zhang BZ, Huang JD, To KK, Yuen KY, Chu H. Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. Cell Rep Med. 2022 Sep 20;3(9):100743. Epub 2022 Aug 29. (IF: 14.3, citations: 20)
  14. Chan JF, Huang X, Hu B, Chai Y, Shi H, Zhu T, Yuen TT, Liu Y, Liu H, Shi J, Wen L, Shuai H, Hou Y, Yoon C, Cai JP, Zhang AJ, Zhou J, Yin F, Yuan S, Zhang BZ, Brindley MA, Shi ZL, Yuen KY, Chu H. Altered host protease determinants for SARS-CoV-2 Omicron. Sci Adv. 2023 Jan 20;9(3):eadd3867. Epub 2023 Jan 20. (IF: 13.6, citations: 10)
  15. Yuan S, Chu H, Huang J, Zhao X, Ye ZW, Lai PM, Wen L, Cai JP, Mo Y, Cao J, Liang R, Poon VK, Sze KH, Zhou J, To KK, Chen Z, Chen H, Jin DY, Chan JF (co-corresponding), Yuen KY. Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target. Sci Adv. 2020 Aug 28;6(35):eaba7910. (IF: 13.6, citations: 32)
  16. Chu H, Shuai H, Hou Y, Zhang X, Wen L, Huang X, Hu B, Yang D, Wang Y, Yoon C, Wong BH, Li C, Zhao X, Poon VK, Cai JP, Wong KK, Yeung ML, Zhou J, Au-Yeung RK, Yuan S, Jin DY, Kok KH, Perlman S, Chan JF (co-corresponding), Yuen KY. Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Sci Adv. 2021 Jun 16;7(25):eabf8577. (IF: 13.6, citations: 42)
  17. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221-236. Epub 2020 Jan 28. (IF: 13.2, citations: 2,084)
  18. Zhang X, Chu H, Chik KK, Wen L, Shuai H, Yang D, Wang Y, Hou Y, Yuen TT, Cai JP, Yuan S, Yin F, Yuen KY, Chan JF (corresponding). hnRNP C modulates MERS-CoV and SARS-CoV-2 replication by governing the expression of a subset of circRNAs and cognitive mRNAs. Emerg Microbes Infect. 2022 Dec;11(1):519-531. Epub 2022 Feb 10. (IF: 13.2, citations: 8)
  19. Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, Chan WM, Fan Z, Tsoi HW, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai JP, Kok KH, Chu H, Chan KH, Sridhar S, Chen Z, Chen H, To KK, Yuen KY. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020 Dec 3;71(9):2428-2446. Epub 2020 Mar 26. (IF: 11.8, citations: 712)
  20. Chan JF, Yuan S, Zhang AJ, Poon VK, Chan CC, Lee AC, Fan Z, Li C, Liang R, Cao J, Tang K, Luo C, Cheng VC, Cai JP, Chu H, Chan KH, To KK, Sridhar S, Yuen KY. Surgical mask partition reduces the risk of non-contact transmission in a golden Syrian hamster model for Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2020 Nov 19;71(16):2139-2149. Epub 2020 May 30. (IF: 11.8, citations: 224)
  21. Chan JF, Poon VK, Chan CC, Chik KK, Tsang JO, Zou Z, Chan CC, Lee AC, Li C, Liang R, Cao J, Tang K, Yuen TT, Hu B, Huang X, Chai Y, Shuai H, Luo C, Cai JP, Chan KH, Sridhar S, Yin F, Kok KH, Chu H, Zhang AJ, Yuan S, Yuen KY. Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters. Clin Infect Dis. 2022 Aug 24;75(1):e1101-e1111. Epub 2021 Sep 18. (IF: 11.8, citations: 11)
  22. Chan JF, Siu GK, Yuan S, Ip JD, Cai JP, Chu AW, Chan WM, Abdullah SMU, Luo C, Chan BP, Yuen TT, Chen LL, Chik KK, Liang R, Cao H, Man Poon VK, Chan CC, Leung KH, Tam AR, Tsang OT, Chan JM, To WK, Lam BH, Lee LK, Lo HW, Wong IT, Leung JS, Wong EY, Chu H, Yip CC, Cheng VC, Chan KH, Tse H, Lung DC, Ng KH, Au AK, Hung IF, Yuen KY, To KK. Probable Animal-to-Human Transmission of SARS-CoV-2 Delta Variant AY.127 Causing a Pet Shop-Related COVID-19 Outbreak in Hong Kong. Clin Infect Dis. 2022 Aug 24;75(1):e76-e81. Epub 2022 Mar 2. (IF: 11.8, citations: 13)
  23. Chan JF (corresponding), Zhang AJ, Chan CC, Yip CC, Mak WW, Zhu H, Poon VK, Tee KM, Zhu Z, Cai JP, Tsang JO, Chik KK, Yin F, Chan KH, Kok KH, Jin DY, Au-Yeung RK, Yuen KY. Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Including Orchitis Effectively Treated by Recombinant Type I Interferons. EBioMedicine. 2016 Dec;14:112-122. Epub 2016 Nov 12. (IF: 11.1, citations: 75)
  24. Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, Fung AY, Ng AC, Zou Z, Tsoi HW, Choi GK, Tam AR, Cheng VC, Chan KH, Tsang OT, Yuen KY. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens. J Clin Microbiol. 2020 Apr 23;58(5):e00310-20. (IF: 9.4, citations: 713)
  25. Chan JF, Choi GK, Tsang AK, Tee KM, Lam HY, Yip CC, To KK, Cheng VC, Yeung ML, Lau SK, Woo PC, Chan KH, Tang BS, Yuen KY. Development and Evaluation of Novel Real-Time Reverse Transcription-PCR Assays with Locked Nucleic Acid Probes Targeting Leader Sequences of Human-Pathogenic Coronaviruses. J Clin Microbiol. Aug;53(8):2722-6. doi: 10.1128/JCM.01224-15. Epub 2015 May 27. (IF: 9.4, citations: 57)
  26. Yan B, Yuan S, Cao J, Fung K, Lai PM, Yin F, Sze KH, Qin Z, Xie Y, Ye ZW, Yuen TT, Chik KK, Tsang JO, Zou Z, Chan CC, Luo C, Cai JP, Chan KH, Chung TW, Tam AR, Chu H, Jin DY, Hung IF, Yuen KY, Kao RY, Chan JF (corresponding). Phosphatidic acid phosphatase 1 impairs SARS-CoV-2 replication by affecting the glycerophospholipid metabolism pathway. Int J Biol Sci. 2022 Jul 11;18(12):4744-4755. (IF: 9.2, citations: 10)
  27. Wen L, Tang K, Chik KK, Chan CC, Tsang JO, Liang R, Cao J, Huang Y, Luo C, Cai JP, Ye ZW, Yin F, Chu H, Jin DY, Yuen KY, Yuan S, Chan JF (corresponding). In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor. Int J Biol Sci. 2021 Apr 10;17(6):1555-1564. (IF: 9.2, citations: 13)
  28. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015;212:1904-13. Epub 2015 Jul 21. (IF: 6.4, citations: 542)
  29. Chan JF, Chan KH, Choi GK, To KK, Tse H, Cai JP, Yeung ML, Cheng VC, Chen H, Che XY, Lau SK, Woo PC, Yuen KY. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis. 2013;207:1743-52. Epub 2013 Mar 26. (IF: 6.4, citations: 178)

Reviews

  1. Chan JF, Yuan S, Chu H, Sridhar S, Yuen KY. COVID-19 drug discovery and treatment options. Nat Rev Microbiol. 2024 (accepted). (IF: 88.1)
  2. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015 Apr;28(2):465-522. (IF: 36.8, citations: 662)
  3. Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013 Oct;21(10):544-55. Epub 2013 Jun 14. (IF: 15.9, citations: 403)
  4. Zumla A, Chan JF (co-first), Azhar EI, Hui DS, Yuen KY. Coronaviruses – drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. Epub 2016 Feb 12. (IF: 120.1, citations: 1,261)

join our team

The Chan laboratory is recruiting MPhil & PhD students, research assistants, and Post-Doc Fellows. Interested candidates please send a cover letter detailing your research interests and CV to Dr. Jasper FW Chan (jfwchan@hku.hk).